Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCB | P05771 | 9/20 | 0.84 |
| ▸ | PRKCA | P17252 | 5/20 | 0.84 |
| ▸ | CDK4 | P11802 | 3/20 | 0.84 |
| ▸ | CCND1 | P24385 | 3/20 | 0.84 |
| ▸ | CDK2 | P24941 | 3/20 | 0.84 |
| ▸ | PRKCH | P24723 | 3/20 | 0.84 |
| ▸ | PRKCE | Q02156 | 3/20 | 0.84 |
| ▸ | PRKCQ | Q04759 | 3/20 | 0.84 |
| ▸ | PRKCD | Q05655 | 3/20 | 0.84 |
| ▸ | CAMK2D | Q13557 | 2/20 | 0.84 |
| ▸ | ABL1 | P00519 | 2/20 | 0.84 |
| ▸ | CCNE2 | O96020 | 2/20 | 0.84 |
| ▸ | PRKACA | P17612 | 2/20 | 0.84 |
| ▸ | PRKACG | P22612 | 2/20 | 0.84 |
| ▸ | PRKACB | P22694 | 2/20 | 0.84 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.84 |
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.84 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.84 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.84 |
| ▸ | PRKCG | P05129 | 1/20 | 0.84 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ro-316233 SCHEMBL29373011 | 0.92 | PRKCB (1.00) | PRKCBPRKCACDK4CCND1CDK2 | |
| Ro-316233 SCHEMBL624896 | 0.92 | PRKCB (1.00) | PRKCBPRKCACDK4CCND1CDK2 | |
| SCHEMBL8160996 | 0.83 | PRKCB (0.67) | PRKCBPRKCACDK4CCND1CDK2 | |
| SCHEMBL2013173 | 0.81 | PRKCB (0.55) | PRKCBPRKCACDK4CCND1CDK2 | |
| SCHEMBL6823304 | 0.81 | PRKCB (0.78) | PRKCBPRKCACDK4CCND1CDK2 | |
| SCHEMBL6098588 | 0.81 | PRKCB (0.78) | PRKCBPRKCACDK4CCND1CDK2 | |
| SCHEMBL5333315 | 0.81 | PRKCB (0.78) | PRKCBPRKCACDK4CCND1CDK2 | |
| SCHEMBL13917970 | 0.81 | PRKCB (0.78) | PRKCBPRKCACDK4CCND1CDK2 | |
| SCHEMBL6583607 | 0.81 | PRKCB (0.58) | PRKCBPRKCACDK4CCND1CDK2 | |
| SCHEMBL8167180 | 0.81 | PRKCB (0.78) | PRKCBPRKCACDK4CCND1CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090304663-A1 | USE OF GSK-3 INHIBITORS FOR THE TREATMENT OF PROSTATE CANCER | IMPERIAL INNOVATIONS LIMITED (GB) | 2009-12-10 | — | — | US | claimed |
| EP-1786448-A1 | USE OF GSK-3 INHIBITORS FOR THE TREATMENT OF PROSTATE CANCER | Imperial Innovations Limited (GB) | 2007-05-23 | — | — | EP | claimed |
| WO-2006018633-A1 | USE OF GSK-3 INHIBITORS FOR THE TREATMENT OF PROSTATE CANCER | IMPERIAL INNOVATIONS LIMITED (GB) | 2006-02-23 | — | — | WO | claimed |
| US-20050075276-A1 | Use of inhibitors of glycogen synthase-3 to augment CD28 dependent -T-cell responses | RUDD CHRISTOPHER (US) | 2005-04-07 | — | — | US | claimed |
| EP-4662319-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | Integrate Bioscience LLC (US) | 2025-12-17 | — | — | EP | disclosed |
| WO-2024168301-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | FUNCTION ONCOLOGY, INC. (US) | 2024-08-15 | — | — | WO | disclosed |
| EP-2125683-B1 | 3-BENZOFURANYL-4-INDOLYL-MALEIMIDES AS POTENT GSK-3 INHIBITORS FOR NEURODEGENERATIVE DISORDERS | UNIV ILLINOIS (US) | 2013-10-23 | — | — | EP | disclosed |
| US-8207216-B2 | Benzofuran-3-yl(indol-3-yl) maleimides as potent GSK3 inhibitors | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2012-06-26 | — | — | US | disclosed |
| US-7799915-B2 | Anilino-pyrimidine analogs | WYETH LLC (US) | 2010-09-21 | — | — | US | disclosed |
| US-20100105745-A1 | Suppression of cancer and method for evaluating anticancer agent based on the effect of inhibiting gsk3 beta | NATIONAL UNIVERSITY CORPORATION KANAZAWA UNIVERSITY (JP) | 2010-04-29 | — | — | US | disclosed |
| US-20100004308-A1 | Benzofuran-3-yl(indol-3-yl) Maleimides as Potent GSK3 Inhibitors | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS, A BODY CORPORATE AND POLITIC OF THE STATE OF ILLINOIS | 2010-01-07 | — | — | US | disclosed |
| US-20090304663-A1 | USE OF GSK-3 INHIBITORS FOR THE TREATMENT OF PROSTATE CANCER | IMPERIAL INNOVATIONS LIMITED (GB) | 2009-12-10 | — | — | US | disclosed |
| US-20020052397-A1 | 3-indolyl-4-phenyl-1H-pyrrole-2,5-dione derivatives as inhibitors of glycogen synthase kinase-3beta | SYNTEX (U.S.A.) LLC | 2002-05-02 | — | — | US | disclosed |
| US-20020052397-A1 | 3-indolyl-4-phenyl-1H-pyrrole-2,5-dione derivatives as inhibitors of glycogen synthase kinase-3beta | SYNTEX (U.S.A.) LLC | 2002-05-02 | — | — | US | disclosed |
| WO-2002010158-A2 | 3-INDOLYL-4-PHENYL-1H-PYRROLE-2,5-DIONE DERIVATIVES AS INHIBITORS OF GLYCOGEN SYNTHASE KINASE-3BETA | F. HOFFMANN-LA ROCHE AG (CH) | 2002-02-07 | — | — | WO | disclosed |
| WO-2002010158-A2 | 3-INDOLYL-4-PHENYL-1H-PYRROLE-2,5-DIONE DERIVATIVES AS INHIBITORS OF GLYCOGEN SYNTHASE KINASE-3BETA | F. HOFFMANN-LA ROCHE AG (CH) | 2002-02-07 | — | — | WO | disclosed |
| US-RE36736-E | Substituted pyrroles | HOFFMAN-LA ROCHE INC. (US) | 2000-06-13 | — | — | US | disclosed |
| EP-0328026-B1 | SUBSTITUTED PYRROLES | F. HOFFMANN-LA ROCHE AG (CH) | 1993-04-28 | — | — | EP | disclosed |
| US-5057614-A | Antiinflammatory, immunology, bronchodilator agents, cardiovascular disorders | HOFFMANN-LA ROCHE INC. (US) | 1991-10-15 | — | — | US | disclosed |
| EP-0328026-A1 | Substituted pyrroles | F. HOFFMANN-LA ROCHE AG (CH) | 1989-08-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004308-A1 | Benzofuran-3-yl(indol-3-yl) Maleimides as Potent GSK3 Inhibitors | GSK3B, GSK3A, GSKIP | PRKCB 720/4885PRKCA 1238/4885CDK4 467/4885 |
| US-20020052397-A1 | 3-indolyl-4-phenyl-1H-pyrrole-2,5-dione derivatives as inhibitors of glycogen synthase kinase-3beta | GSK3B, GSK3A, PYGL | PRKCB 62/4885PRKCA 61/4885CDK4 368/4885 |
| US-20100105745-A1 | Suppression of cancer and method for evaluating anticancer agent based on the effect of inhibiting gsk3 beta | GSK3B, GSK3A, GSKIP | PRKCB 228/4885PRKCA 356/4885CDK4 409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.